Pilot Study of the Impact of Giant Cell Arteritis and Its Treatment on the Autonomy of the Elderly in the First Year of Care

Overview

Giant cell arteritis is the leading cause of vasculitis in the elderly. No work evaluates its impact on autonomy. At the diagnosis a gerontological evaluation will be carried out including the scores ADL, iADL, MNA, SF 36, SPPB, FRIED and GDS. A monthly telephone reassessment will collect ADL and iADL. The end-of-study consultation at M12, conducted by a geriatrician, will have the same scores as at M0. This will make it possible to evaluate the difference in the functional autonomy score between M0 and M12 in the elderly with ACG.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 17, 2022

Interventions

  • Other: Assessment by questionnaire
    • At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient. A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS

Arms, Groups and Cohorts

  • assessment by questionnaire

Clinical Trial Outcome Measures

Primary Measures

  • Activities of Daily Living (ADL)
    • Time Frame: Month 12
    • Compare score between Month 0 and Month 12. The scale is evaluated from 0 (dependence) to 6 (autonomy).

Secondary Measures

  • Activities of Daily Living (ADL)
    • Time Frame: Month 11
    • Compare the evolution every month at M0 and every month up to Month 11 The scale is evaluated from 0 (dependence) to 6 (autonomy).

Participating in This Clinical Trial

Inclusion Criteria

  • Age greater than or equal to 65 years with at least 2 comorbidities * present, or age greater than or equal to 75 years – Diagnosis of ACG meeting the diagnostic criteria of ACG 1990 ACR – comorbidity = chronic pathology Exclusion Criteria:
  • Neoplastic pathology under treatment – Brain pathology with motor disability – Dementia at a severe stage (MMS <22/30) – Unable to answer the phone – Participation in a therapeutic clinical trial
  • Gender Eligibility: All

    Minimum Age: 65 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • University Hospital, Limoges
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Contact(s)
      • Anne Laure FAUCHAIS, PU PH, + 33 555 058 076, anne-laure.fauchais@chu-limoges.fr

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.